At a glance
ClinicalIndex Comparison RecordN/ACompleted· 537 enrolled
Drug / intervention
1: AID groups +1 moreother
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Clinical and Multi-omics Cross-phenotyping of Patients With Autoimmune and Auto-inflammatory Diseases
In Brief
An observational study evaluating 1: AID groups and 2: Control groups for Healthy Volunteer and 12 related conditions. Completed, enrolled 537 participants across 2 sites.
Detailed Summary
The family of inflammatory/autoimmune systemic diseases (IAD) form a continuum from pure inflammatory diseases to pure autoimmune diseases, encompassing a large panel of inflammatory diseases with some autoimmune components, and vice versa. Cross phenotyping of patients with IAD should be heuristic and help revise the nosography and the understanding of these diseases.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteer, Rheumatoid Arthritis, Ankylosing Spondylitis, Systemic Lupus Erythematosus/Antiphospholipid Syndrome, FMF, Cryopyrin-Associated Periodic Syndromes /TNF-receptor Associated Periodic Syndrome, Vasculitis, Uveitis, Myositis, Crohn's Disease, Ulcerative Rectocolitis, Type 1 Diabetes, Unclassified IAD Knee and/or Hip Arthritis, Muscular Dystrophy
CountriesFrance
CollaboratorsNational Research Agency, France
Timeline
N/ACompletedFinished
20162017201820192020202120222023202420252026
First PostedJun 2015
Enrollment StartJul 2015
Primary CompletionJul 2022
Study CompletionJul 2022
TodayJul 2026
First PostedJun 9, 2015
Enrollment StartJul 29, 2015
Primary CompletionJul 14, 2022
Study CompletionJul 18, 2022
TodayJul 2, 2026
Enrollment to primary: 7.0 yearsPosted 11.1 years ago
Interventions
1: AID groupsother
Clinical and Biological investigations
2: Control groupsother
Clinical and Biological investigations